Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
2.
Genet Mol Res ; 12(2): 1490-500, 2013 May 06.
Artículo en Inglés | MEDLINE | ID: mdl-23765956

RESUMEN

Liver receptor homologue 1 (Lrh-1) is a member of the nuclear receptor belonging to the second subfamily of the nuclear receptor family 5A (NR5A), also named NR5A2, which is important for lipid homeostasis, embryogenesis, and regulation of aromatics. The present study aimed to understand the sequence of ovine Lrh-1 and the expression traits in reproductive organ tissues. Initially, we cloned Lrh-1 from the liver of Hu sheep through degenerate primer of reverse transcription-polymerase chain reaction and rapid amplification of cDNA ends. Characteristic functional domains of DNA binding and ligand binding, conserved among transcription factors of the nuclear receptor superfamily, were identified in Lrh-1 of Hu sheep. The Lrh-1 protein levels in the tissues detected by Western blotting correlated significantly with the transcript levels measured by quantitative real-time polymerase chain reaction (qRT-PCR). To understand the Lrh-1 expression change in the hypothalamus and hypophysis during the estrous cycle, we analyzed the expression pattern of Lrh-1 mRNA and protein by qRT-PCR and Western blotting, respectively. This analysis revealed that Lrh-1 expression in the hypothalamus was highest during the metestrus phase, while the Lrh-1 level was similar during other phases. In the hypophysis, the expression was significantly different during the 4 phases of the estrous cycle but highest during the estrus phase, significantly correlating with FSH concentration. These results indicate that Lrh-1 expression is correlated with gonadotropic hormone secretion, influencing follicular formation in the ovary.


Asunto(s)
Regulación de la Expresión Génica , Receptores Citoplasmáticos y Nucleares/genética , Ovinos/genética , Secuencia de Aminoácidos , Animales , China , Clonación Molecular , Ciclo Estral , Femenino , Perfilación de la Expresión Génica , Sistema Hipotálamo-Hipofisario/metabolismo , Hígado/metabolismo , Datos de Secuencia Molecular , Oviductos/metabolismo , Receptores Citoplasmáticos y Nucleares/sangre , Receptores Citoplasmáticos y Nucleares/química , Alineación de Secuencia , Ovinos/sangre , Ovinos/clasificación
4.
Bone ; 47(1): 5-11, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20362079

RESUMEN

In the present study, we systematically examined telmisartan, an angiotensin AT(1) receptor antagonist, on rosiglitazone-induced bone loss in ovariectomized spontaneously hypertensive rats. Telmisartan (5 mg/kg/d, 90 days) was found to be able to significantly alleviate rosiglitazone (10 mg/kg/d, 90 days)-induced decrease in BMD of femur and lumbar vertebrae. The BMD changes were associated with positive biomechanical changes of lumbar vertebrae, improvements in microarchitecture of tibial metaphysic and normalized serum osteocalcin (OC) levels and urinary deoxypyridinoline/creatinine (DPD/Cr) ratio. MicroCT analysis of the tibial metaphysis showed that telmisartan significantly prevented the decreases in bone volume/tissue volume (BV/TV), connect density (Conn. D.), trabecular number (Tb. N.) and trabecular thickness (Tb. Th.), and increase in trabecular separation (Tb. Sp.) induced by rosiglitazone. Histomorphometric analysis also showed that telmisartan had protective effects on rosiglitazone-reduced bone formation indices such as histomorphometric bone volume fraction (BV/TV-Histo), mineralizing surface/bone surface (MS/BS), mineral apposition rate (MAR) and bone formation rate (BFR/BS). Our study clearly showed that telmisartan alleviated rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats. The relief of bone loss provides a possible therapeutic application of telmisartan with rosiglitazone for the treatment of elderly women patients afflicted with metabolic syndrome.


Asunto(s)
Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Bencimidazoles/uso terapéutico , Benzoatos/uso terapéutico , Resorción Ósea/tratamiento farmacológico , Resorción Ósea/prevención & control , Ovariectomía , Tiazolidinedionas/efectos adversos , Bloqueadores del Receptor Tipo 1 de Angiotensina II/farmacología , Animales , Bencimidazoles/farmacología , Benzoatos/farmacología , Biomarcadores/metabolismo , Fenómenos Biomecánicos/efectos de los fármacos , Presión Sanguínea/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Densidad Ósea/efectos de los fármacos , Remodelación Ósea/efectos de los fármacos , Resorción Ósea/fisiopatología , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Vértebras Lumbares/efectos de los fármacos , Vértebras Lumbares/fisiopatología , Ratas , Ratas Endogámicas SHR , Rosiglitazona , Sístole/efectos de los fármacos , Telmisartán , Tibia/diagnóstico por imagen , Tibia/efectos de los fármacos , Tibia/patología , Tibia/fisiopatología , Factores de Tiempo , Microtomografía por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA